FDA approval for Rolvedon injection for management of severe chemotherapy- induced neutropenia.- Spectrum Pharma
Spectrum Pharmaceuticals, Inc. announced that the FDA has approved Rolvedon (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
“Rolvedon’s approval marks Spectrum’s transformation to a commercial-stage company with the opportunity to compete in a $2 billion dollar market, and offers a unique value proposition,” said Tom Riga, President and Chief Executive Officer of Spectrum Pharmaceuticals. “This approval is a significant milestone for our development team and collaboration with Hanmi Pharmaceutical. ”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.